FDA panel endorses novel tuberculosis drug

SILVER SPRING, Maryland — A federal advisory panel voted unanimously yesterday 18 to 0 for efficacy but split 11 to 7 on safety in support of accelerated approval of a novel drug to combat multidrug-resistant tuberculosis (MDR-TB).